Hospital
Forrest County General Hospital
Forrest County General Hospital was paid $81.63M by Medicaid between Jan 2018 and Dec 2024, across 433 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoFORREST COUNTY GENERAL HOSPITAL
HATTIESBURG, MS 39401
HATTIESBURG, MS 39401
33aNPI1225041809assigned 08/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$81.63M
24GClaims2,224,890
24DCodes billed433
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#4 of 77
Median peer was paid$8.23M
This provider vs. median9.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HESTER, BEN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 339,436 | $12.72M | |
| 2019 | 339,543 | $13.11M | |
| 2020 | 265,287 | $10.58M | |
| 2021 | 274,882 | $10.76M | |
| 2022 | 331,692 | $11.01M | |
| 2023 | 385,432 | $13.93M | |
| 2024incomplete | 288,618 | $9.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 57,830 | 47,042 | $11.70M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 49,867 | 40,049 | $8.87M |
| G0378 | Hospital observation service, per hour | 10% | 21,139 | 16,161 | $8.56M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.5% | 37,280 | 31,581 | $5.28M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 36,294 | 27,947 | $3.05M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.8% | 676 | 419 | $2.26M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.5% | 22,744 | 11,191 | $2.03M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 23,275 | 18,373 | $1.90M |
| 77386 | 2.0% | 10,789 | 830 | $1.64M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 10,301 | 8,835 | $1.52M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.7% | 9,759 | 5,623 | $1.43M |
| J9299 | Injection, nivolumab, 1 mg | 1.6% | 813 | 278 | $1.27M |
421 more codes
| 71045 | Radiologic examination, chest; single view | 1.5% | 36,916 | $1.19M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 3,688 | $1.06M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 11,008 | $1.06M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 26,729 | $958K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 54,183 | $956K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 18,809 | $881K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 21,217 | $825K |
| 93458 | <1% | 831 | $769K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,590 | $729K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,001 | $716K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 4,377 | $699K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37,826 | $665K |
| 86900 | <1% | 15,101 | $657K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,518 | $650K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,721 | $632K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 552 | $618K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,602 | $601K |
| 77301 | <1% | 1,129 | $567K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 114,817 | $536K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,755 | $508K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,812 | $491K |
| 77334 | <1% | 1,722 | $423K | |
| 36430 | <1% | 4,187 | $411K | |
| 49083 | <1% | 1,922 | $381K | |
| 77300 | <1% | 2,310 | $364K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,312 | $363K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 57,425 | $334K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,206 | $302K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 877 | $293K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 7,424 | $291K |
| 77336 | <1% | 5,599 | $283K | |
| 86850 | <1% | 14,070 | $279K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 8,705 | $274K |
| 84484 | <1% | 34,556 | $269K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,550 | $265K |
| 82553 | <1% | 32,422 | $252K | |
| 80053 | Comprehensive metabolic panel | <1% | 41,089 | $246K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 7,426 | $240K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 378 | $229K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,073 | $223K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,038 | $208K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,185 | $206K |
| 36415 | Collection of venous blood by venipuncture | <1% | 96,790 | $199K |
| 86901 | <1% | 15,321 | $198K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,717 | $194K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 3,618 | $189K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,118 | $188K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,598 | $171K |
| 77412 | <1% | 2,344 | $170K | |
| 76801 | <1% | 2,594 | $169K | |
| 86923 | <1% | 2,749 | $156K | |
| 96367 | <1% | 5,344 | $155K | |
| 93017 | <1% | 3,355 | $153K | |
| 88307 | <1% | 1,159 | $153K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 242 | $151K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,885 | $151K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,458 | $147K |
| 74018 | <1% | 3,448 | $143K | |
| 82550 | <1% | 38,300 | $141K | |
| 77338 | <1% | 1,308 | $136K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,377 | $136K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 11,730 | $130K |
| 36600 | <1% | 4,230 | $130K | |
| 83880 | <1% | 7,186 | $125K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 14,476 | $124K |
| 85730 | <1% | 36,548 | $123K | |
| 73562 | <1% | 3,414 | $122K | |
| 81001 | <1% | 58,658 | $121K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,690 | $119K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,131 | $119K |
| 94762 | <1% | 1,572 | $118K | |
| 72100 | <1% | 2,302 | $118K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,379 | $113K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,578 | $108K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,615 | $107K |
| 85610 | <1% | 45,709 | $106K | |
| 73630 | <1% | 2,721 | $102K | |
| 86920 | <1% | 1,311 | $100K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,764 | $99K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,337 | $96K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,801 | $95K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,794 | $95K |
| 82962 | <1% | 41,134 | $92K | |
| 80069 | <1% | 19,790 | $89K | |
| 87040 | <1% | 9,836 | $89K | |
| 73030 | <1% | 2,623 | $88K | |
| 95816 | <1% | 643 | $86K | |
| 93971 | <1% | 2,288 | $85K | |
| 73130 | <1% | 2,128 | $84K | |
| 73610 | <1% | 2,036 | $82K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,251 | $80K |
| 96417 | <1% | 2,486 | $77K | |
| 82803 | <1% | 5,476 | $76K | |
| 70486 | <1% | 1,547 | $75K | |
| 93970 | <1% | 1,010 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,367 | $72K |
| 96415 | <1% | 1,715 | $70K | |
| 81025 | <1% | 12,730 | $70K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 536 | $69K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,513 | $67K |
| 80076 | <1% | 11,679 | $66K | |
| 83690 | <1% | 14,475 | $64K | |
| 87581 | <1% | 2,834 | $64K | |
| 86922 | <1% | 856 | $62K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,709 | $60K |
| 97161 | <1% | 2,359 | $59K | |
| 97597 | <1% | 1,402 | $59K | |
| 87077 | <1% | 9,356 | $59K | |
| 87186 | <1% | 8,968 | $59K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 877 | $59K |
| 87641 | <1% | 2,395 | $58K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 88 | $57K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 931 | $56K |
| 77470 | <1% | 363 | $54K | |
| 77385 | <1% | 232 | $54K | |
| 73590 | <1% | 1,467 | $52K | |
| 84703 | <1% | 9,778 | $52K | |
| 74019 | <1% | 854 | $51K | |
| 83605 | <1% | 8,808 | $49K | |
| 84702 | <1% | 4,810 | $48K | |
| 97162 | <1% | 1,356 | $48K | |
| 83735 | <1% | 12,610 | $47K | |
| 59025 | Fetal non-stress test | <1% | 426 | $44K |
| 73090 | <1% | 1,120 | $44K | |
| 87430 | <1% | 3,646 | $43K | |
| 80061 | Lipid panel | <1% | 4,894 | $41K |
| 87070 | <1% | 6,484 | $41K | |
| 73502 | <1% | 1,479 | $40K | |
| 82247 | <1% | 4,301 | $40K | |
| 74022 | <1% | 609 | $40K | |
| 88304 | <1% | 1,554 | $40K | |
| 47563 | <1% | 20 | $38K | |
| 72131 | <1% | 855 | $37K | |
| 70496 | <1% | 755 | $36K | |
| 77295 | <1% | 58 | $36K | |
| 73700 | <1% | 865 | $36K | |
| 73110 | <1% | 929 | $35K | |
| D0272 | Bitewings - two radiographic images | <1% | 58 | $35K |
| 70498 | <1% | 764 | $35K | |
| 77290 | <1% | 216 | $34K | |
| 86902 | <1% | 168 | $31K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 60 | $29K |
| 72170 | <1% | 765 | $28K | |
| 73552 | <1% | 877 | $28K | |
| 87427 | <1% | 2,792 | $28K | |
| 12001 | <1% | 322 | $27K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 252 | $27K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,295 | $25K |
| 71250 | <1% | 873 | $24K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 718 | $24K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 355 | $23K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 262 | $23K |
| 97116 | <1% | 2,667 | $22K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 25 | $22K |
| 84146 | <1% | 1,434 | $22K | |
| 87205 | <1% | 5,924 | $22K | |
| 85379 | <1% | 3,899 | $22K | |
| 87420 | <1% | 1,824 | $21K | |
| 73080 | <1% | 540 | $21K | |
| 87081 | <1% | 3,464 | $20K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 159 | $19K |
| 85027 | <1% | 3,905 | $19K | |
| 51702 | <1% | 469 | $19K | |
| 88112 | <1% | 959 | $18K | |
| 97533 | <1% | 411 | $18K | |
| 87634 | <1% | 344 | $18K | |
| 29581 | <1% | 817 | $18K | |
| 99205 | Prolong outpt/office vis | <1% | 242 | $18K |
| 27447 | <1% | 21 | $18K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 59 | $17K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 3,434 | $17K |
| 86738 | <1% | 1,557 | $17K | |
| C1776 | Joint device (implantable) | <1% | 361 | $17K |
| 87493 | <1% | 846 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,104 | $16K |
| 82150 | <1% | 3,575 | $16K | |
| 36561 | <1% | 16 | $15K | |
| 93880 | <1% | 317 | $15K | |
| 96411 | <1% | 382 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 225 | $15K |
| A9270 | Non-covered item or service | <1% | 38,191 | $15K |
| 86140 | <1% | 4,673 | $14K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 194 | $14K |
| 87046 | <1% | 1,838 | $13K | |
| 96416 | <1% | 86 | $13K | |
| 31624 | <1% | 47 | $12K | |
| 36592 | <1% | 38,257 | $12K | |
| 88342 | <1% | 227 | $12K | |
| 73060 | <1% | 348 | $11K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 554 | $11K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 116 | $11K |
| 62270 | <1% | 31 | $11K | |
| 76770 | <1% | 145 | $11K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 72 | $10K |
| 85007 | <1% | 3,524 | $10K | |
| 84100 | <1% | 3,365 | $9K | |
| 82607 | <1% | 1,323 | $9K | |
| 82140 | <1% | 1,166 | $9K | |
| 82565 | <1% | 2,700 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 354 | $9K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 89 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,084 | $9K |
| 86481 | <1% | 308 | $9K | |
| 36573 | <1% | 26 | $8K | |
| 31628 | <1% | 16 | $8K | |
| 82010 | <1% | 1,514 | $8K | |
| 97166 | <1% | 360 | $8K | |
| 85044 | <1% | 2,894 | $7K | |
| 85651 | <1% | 2,712 | $7K | |
| 12002 | <1% | 87 | $7K | |
| 81003 | <1% | 4,418 | $7K | |
| 84439 | <1% | 1,233 | $6K | |
| 82728 | <1% | 977 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 138 | $6K |
| 86308 | <1% | 1,584 | $6K | |
| 92523 | <1% | 94 | $5K | |
| 12011 | <1% | 58 | $5K | |
| 85049 | <1% | 1,998 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 357 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,380 | $5K |
| 93312 | <1% | 43 | $5K | |
| 83615 | <1% | 1,230 | $4K | |
| 83550 | <1% | 1,080 | $4K | |
| 87147 | <1% | 168 | $4K | |
| 85014 | <1% | 3,094 | $4K | |
| 87102 | <1% | 746 | $4K | |
| 84520 | <1% | 1,662 | $4K | |
| 85018 | <1% | 2,969 | $4K | |
| 87483 | <1% | 13 | $4K | |
| 73560 | <1% | 149 | $4K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 29 | $4K |
| 32555 | <1% | 20 | $4K | |
| 97014 | <1% | 495 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $4K |
| 94760 | <1% | 23,572 | $4K | |
| 51798 | <1% | 438 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,884 | $4K |
| 83540 | <1% | 1,180 | $4K | |
| 84550 | <1% | 1,238 | $3K | |
| 88312 | <1% | 157 | $3K | |
| 84132 | <1% | 1,422 | $3K | |
| 80202 | <1% | 363 | $3K | |
| 76885 | <1% | 55 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 248 | $3K |
| 93798 | <1% | 54 | $3K | |
| 80074 | <1% | 94 | $3K | |
| 78582 | <1% | 16 | $2K | |
| 97165 | <1% | 97 | $2K | |
| C1769 | Guide wire | <1% | 4,001 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 51 | $2K |
| 93296 | <1% | 385 | $2K | |
| 90686 | <1% | 230 | $2K | |
| 87184 | <1% | 344 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 134 | $2K |
| 82570 | <1% | 662 | $2K | |
| 82746 | <1% | 202 | $2K | |
| 88142 | <1% | 149 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 138 | $2K |
| D0350 | <1% | 115 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 50 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 41 | $2K |
| 72050 | <1% | 33 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 857 | $2K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 829 | $2K |
| 86769 | <1% | 54 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,262 | $2K |
| 94761 | <1% | 6,353 | $2K | |
| 86592 | <1% | 698 | $2K | |
| 92610 | <1% | 133 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 44 | $2K |
| 49465 | <1% | 27 | $2K | |
| 87206 | <1% | 310 | $1K | |
| 10060 | <1% | 16 | $1K | |
| 74230 | <1% | 16 | $1K | |
| 84157 | <1% | 689 | $1K | |
| 87631 | <1% | 1,947 | $1K | |
| 87116 | <1% | 213 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15,016 | $1K |
| 89051 | <1% | 488 | $1K | |
| 70360 | <1% | 28 | $1K | |
| 87075 | <1% | 219 | $1K | |
| 87150 | <1% | 85 | $1K | |
| 87210 | <1% | 388 | $1K | |
| 86677 | <1% | 101 | $1K | |
| 77280 | <1% | 20 | $1K | |
| 72158 | <1% | 14 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 21,022 | $1K |
| 96368 | <1% | 2,346 | $1K | |
| 92611 | <1% | 15 | $986.74 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 162 | $973.16 |
| 96376 | <1% | 11,364 | $964.38 | |
| 84156 | <1% | 408 | $908.12 | |
| 29125 | <1% | 17 | $895.36 | |
| 82272 | <1% | 515 | $894.81 | |
| 84145 | <1% | 5,790 | $890.98 | |
| 71101 | <1% | 15 | $851.17 | |
| 82248 | <1% | 251 | $842.08 | |
| 72141 | <1% | 13 | $836.02 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 95 | $779.88 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 36,609 | $758.31 |
| 84450 | <1% | 228 | $723.72 | |
| 86706 | <1% | 110 | $714.28 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 3,146 | $699.19 |
| 93225 | <1% | 41 | $634.97 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,951 | $618.80 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14,376 | $592.84 |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 55 | $585.84 |
| J2704 | Injection, propofol, 10 mg | <1% | 15,956 | $543.60 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,516 | $492.15 |
| D1351 | Sealant - per tooth | <1% | 13 | $480.21 |
| 88173 | <1% | 19 | $477.72 | |
| 82945 | <1% | 186 | $476.90 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 999 | $476.70 |
| 93226 | <1% | 34 | $411.94 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 588 | $363.77 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 12,129 | $363.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,483 | $344.54 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13,012 | $341.45 |
| 82042 | <1% | 97 | $318.51 | |
| 87425 | <1% | 36 | $302.74 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 7,812 | $285.83 |
| 72020 | <1% | 14 | $274.04 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 468 | $242.32 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,876 | $240.09 |
| 87176 | <1% | 73 | $211.44 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 3,012 | $209.00 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,566 | $199.99 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,514 | $197.69 |
| 93282 | <1% | 13 | $196.63 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 12,612 | $191.38 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 586 | $186.99 |
| 89050 | <1% | 48 | $166.36 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,831 | $152.75 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 3,315 | $150.38 |
| 90653 | <1% | 16 | $148.86 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 149 | $121.34 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,835 | $115.94 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,462 | $115.27 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 4,728 | $104.82 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,728 | $97.08 |
| 90714 | <1% | 1,228 | $95.43 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 94 | $92.43 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,447 | $84.67 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 2,793 | $83.62 |
| 84153 | <1% | 13 | $80.58 | |
| 87449 | <1% | 17 | $78.91 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,914 | $60.66 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 977 | $57.39 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,379 | $54.61 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 238 | $50.93 |
| 94660 | <1% | 931 | $43.56 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,290 | $43.09 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 452 | $40.60 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 405 | $37.32 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 413 | $35.78 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,275 | $31.07 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,517 | $30.84 |
| 74300 | <1% | 15 | $28.09 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 841 | $27.02 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 361 | $26.80 |
| G0008 | Administration of influenza virus vaccine | <1% | 103 | $22.41 |
| 94668 | <1% | 29 | $20.84 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 507 | $19.64 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 15 | $19.20 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,161 | $18.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 38 | $17.38 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,239 | $13.92 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 382 | $13.11 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 471 | $12.68 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 4,015 | $11.73 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 216 | $11.18 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 201 | $6.97 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 269 | $6.58 |
| 90715 | <1% | 77 | $5.85 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 18 | $4.90 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 1,137 | $4.31 |
| J1240 | Injection, dimenhydrinate, up to 50 mg | <1% | 279 | $4.20 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 33 | $2.05 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 722 | $1.30 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 201 | $1.24 |
| C1729 | Catheter, drainage | <1% | 13 | $0.64 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 250 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 2,090 | $0.00 |
| 88341 | 0% | 49 | $0.00 | |
| 36591 | 0% | 215 | $0.00 | |
| 77001 | 0% | 329 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 91 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 82 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 145 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 177 | $0.00 |
| 93320 | 0% | 43 | $0.00 | |
| Q0112 | All potassium hydroxide (koh) preparations | 0% | 19 | $0.00 |
| 76377 | 0% | 162 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 75 | $0.00 |
| 29826 | 0% | 14 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 35 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 18 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 21 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 16 | $0.00 |
| A9567 | Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries | 0% | 16 | $0.00 |
| 88311 | 0% | 16 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 2,343 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 88 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 58 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 175 | $0.00 |
| 93325 | 0% | 44 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 141 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 349 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 56 | $0.00 |
| 94667 | 0% | 16 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 32 | $0.00 |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 190 | $0.00 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0% | 24 | $0.00 |
| 51701 | 0% | 15 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 19 | $0.00 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 0% | 82 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 14 | $0.00 |
| 76937 | 0% | 17 | $0.00 | |
| 77387 | 0% | 762 | $0.00 | |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 27 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESTER, BEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Forrest County General Hospital | Picayune, MS | $21.66M |
| Forrest County General Hospital | Columbia, MS | $9.51M |
| Walthall General Hospital | Tylertown, MS | $6.16M |
| Forrest County General Hospital | Prentiss, MS | $3.80M |
| Forrest County General Hospital | Poplarville, MS | $3.74M |
| Forrest County General Hospital | Poplarville, MS | $2.80M |
| Forrest County General Hospital | Picayune, MS | $2.76M |
| Forrest County General Hospital | Richton, MS | $1.58M |
| Forrest County General Hospital | Richton, MS | $1.36M |
| Forrest County General Hospital | Columbia, MS | $1.03M |
| Walthall General Hospital | Tylertown, MS | $953K |
| Forrest General Hospital | Hattiesburg, MS | $850K |
| Forrest County General Hospital | Poplarville, MS | $253K |
| FGH Physician Billing | Hattiesburg, MS | $224K |
| Forrest County General Hospital | Prentiss, MS | $204K |
| Forrest County General Hospital | Picayune, MS | $65K |
| FGH Trauma Surgery Clinic | Hattiesburg, MS | $47K |
| Forrest County General Hospital | Poplarville, MS | $22K |
| Forrest County General Hospital | Richton, MS | $18K |
| Walthall General Hospital | Tylertown, MS | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.